自己免疫疾患治療薬の世界市場2018-2022

◆英語タイトル:Global Autoimmune Drugs Market 2018-2022
◆商品コード:IRTNTR21800
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月14日
◆ページ数:124
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、自己免疫疾患治療薬の世界市場について調査・分析し、市場概要、市場環境、自己免疫疾患治療薬市場規模、治療分野別(関節リウマチ、多発性硬化症、乾癬、炎症性腸疾患、その他)分析、分子種類別(生物製剤、小分子)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・自己免疫疾患治療薬の世界市場概要
・自己免疫疾患治療薬の世界市場環境
・自己免疫疾患治療薬の世界市場動向
・自己免疫疾患治療薬の世界市場規模
・自己免疫疾患治療薬の世界市場:業界構造分析
・自己免疫疾患治療薬の世界市場:治療分野別(関節リウマチ、多発性硬化症、乾癬、炎症性腸疾患、その他)
・自己免疫疾患治療薬の世界市場:分子種類別(生物製剤、小分子)
・自己免疫疾患治療薬の世界市場:地域別市場規模・分析
・自己免疫疾患治療薬の北米市場規模・予測
・自己免疫疾患治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・自己免疫疾患治療薬のアジア太平洋市場規模・予測
・自己免疫疾患治療薬の主要国分析
・自己免疫疾患治療薬の世界市場:意思決定フレームワーク
・自己免疫疾患治療薬の世界市場:成長要因、課題
・自己免疫疾患治療薬の世界市場:競争環境
・自己免疫疾患治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、AbbVie、Amgen、Johnson & Johnson、Novartis、Pfizer、and UCBなどです。
【レポートの概要】

About this market
High cost of autoimmune drugs to drive market growth. Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs. Technavio’ s analysts have predicted that the autoimmune drugs market will register a CAGR of more than 8% by 2022.
Market Overview
Targeted therapeutic mechanism of biologics
By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.
Reimbursement challenges of autoimmune drugs
The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.
For the detailed list of factors that will drive and challenge the growth of the autoimmune drugs market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company the competitive environment is quite intense. Factors such as the targeted therapeutic mechanism of biologics and the high cost of autoimmune drugs, will provide considerable growth opportunities to autoimmune drugs manufactures. AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, and UCB are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY THERAPY AREA
• Segmentation by therapy area
• Comparison by therapy area
• Rheumatoid arthritis – Market size and forecast 2017-2022
• Multiple sclerosis – Market size and forecast 2017-2022
• Psoriasis – Market size and forecast 2017-2022
• Inflammatory bowel disease – Market size and forecast 2017-2022
• Others – Market size and forecast 2017-2022
• Market opportunity by therapy area
PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULE
• Segmentation by type of molecule
• Biologics
• Small molecules
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB
PART 17: APPENDIX
• List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: mAbs and biologics for autoimmune diseases
Exhibit 06: Small molecules for autoimmune diseases
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2017
Exhibit 09: Validation techniques employed for market sizing 2017
Exhibit 10: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 11: Biosimilars approved in 2017
Exhibit 12: Global – Year-over-year growth 2018-2022 (%)
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition – Five forces 2017
Exhibit 21: Therapy area – Market share 2017-2022 (%)
Exhibit 22: Comparison by therapy area
Exhibit 23: Rheumatoid arthritis – Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Rheumatoid arthritis – Year-over-year growth 2018-2022 (%)
Exhibit 25: Multiple sclerosis – Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Multiple sclerosis – Year-over-year growth 2018-2022 (%)
Exhibit 27: Psoriasis – Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Psoriasis – Year over year growth 2018-2022 (%)
Exhibit 29: Inflammatory bowel disease – Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Inflammatory bowel disease – Year-over-year growth 2018-2022 (%)
Exhibit 31: Others – Market size and forecast 2017-2022 ($ bn)
Exhibit 32: Others – Year-over-year growth 2018-2022 (%)
Exhibit 33: Market opportunity by therapy area
Exhibit 34: Customer landscape
Exhibit 35: Global – Market share by geography 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Molecules in the pipeline for autoimmune disorders in the Americas
Exhibit 39: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in Americas
Exhibit 41: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 42: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in EMEA
Exhibit 44: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 45: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 46: Top 3 countries in APAC
Exhibit 47: Market opportunity
Exhibit 48: Sales of major autoimmune drugs
Exhibit 49: Patent expiration dates for some of the biologics
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AbbVie overview
Exhibit 56: AbbVie – Business segments
Exhibit 57: AbbVie – Organizational developments
Exhibit 58: AbbVie – Geographic focus
Exhibit 59: AbbVie – Key offerings
Exhibit 60: Amgen overview
Exhibit 61: Amgen – Business segments
Exhibit 62: Amgen – Organizational developments
Exhibit 63: Amgen – Geographic focus
Exhibit 64: Amgen – Key offerings
Exhibit 65: Johnson & Johnson overview
Exhibit 66: Johnson & Johnson – Business segments
Exhibit 67: Johnson & Johnson – Organizational developments
Exhibit 68: Johnson & Johnson – Geographic focus
Exhibit 69: Johnson & Johnson – Segment focus
Exhibit 70: Johnson & Johnson – Key offerings
Exhibit 71: Novartis overview
Exhibit 72: Novartis – Business segments
Exhibit 73: Novartis – Organizational developments
Exhibit 74: Novartis – Geographic focus
Exhibit 75: Novartis – Segment focus
Exhibit 76: Novartis – Key offerings
Exhibit 77: Pfizer overview
Exhibit 78: Pfizer – Business segments
Exhibit 79: Pfizer – Organizational developments
Exhibit 80: Pfizer – Geographic focus
Exhibit 81: Pfizer – Segment focus
Exhibit 82: Pfizer – Key offerings
Exhibit 83: UCB overview
Exhibit 84: UCB – Business segments
Exhibit 85: UCB – Organizational developments
Exhibit 86: UCB – Geographic focus
Exhibit 87: UCB – Segment focus
Exhibit 88: UCB – Key offerings




【掲載企業】

AbbVie、Amgen、Johnson & Johnson、Novartis、Pfizer、and UCB

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[自己免疫疾患治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆